Cannabis-derived nanovesicles show early promise against tumors in mice

Scientists have grown cannabis plants in laboratory dishes and extracted tiny particles from their roots that appear to wake up the immune system and slow tumor growth in mice. The work, published in NPJ Science of Food, represents an early-stage exploration of whether plant-derived nanomaterials might one day help fight cancer, though the researchers are careful to note that much more work lies ahead.

The team started by establishing what's called a hairy root culture—a system where cannabis plants are genetically transformed to grow roots continuously in liquid medium, without soil. This approach offers a controlled, repeatable way to produce biological materials. From these roots, researchers isolated nanovesicles, spherical particles roughly 113 nanometers across, small enough to survive the journey through the digestive system when given by mouth. The particles carried a diverse chemical cargo: amino acids, carbohydrates, and lipids reflecting the plant's own metabolism. Lab tests showed they remained stable under conditions mimicking digestion, heat, and exposure to stomach enzymes.

When the researchers introduced these cannabis-derived nanovesicles to immune cells in culture, something notable happened. Dendritic cells—the immune system's scouts and messengers—matured and became more active. They displayed more of the molecular flags that signal "wake up" to other immune cells, and they began pumping out inflammatory signaling molecules like tumor necrosis factor-alpha and interleukin-6. The mature dendritic cells then primed T cells, the immune system's foot soldiers, pushing them toward aggressive Th1 and Th17 phenotypes rather than the more tolerant Th2 type. The mechanism appeared to involve two key immune receptors called TLR2 and TLR4, though the exact nature of the interaction remains unclear.

In living mice, the picture became more complex but still suggestive. When researchers gave the nanovesicles by mouth to mice whose immune systems had been suppressed by chemotherapy, some immune function returned. Splenic T cells rebounded, liver damage markers improved, and antioxidant defenses recovered. In a separate experiment, mice bearing E.G7 lymphoma tumors that received oral doses of the nanovesicles showed slower tumor growth compared to controls. The tumors in treated mice had more dendritic cell markers and stronger Th1 and cytotoxic T cell signatures.

But here is where the researchers themselves pump the brakes. The tumor study used only five mice per group. It tested a single dose without comparing to a known cancer drug. It measured immune responses in the spleen, not inside the tumor where the real battle happens. The work did not track whether the nanovesicles actually reach the bloodstream after being swallowed, how long they persist, or where they accumulate in the body. No long-term safety data exists. The authors describe their antitumor findings as preliminary—a word that appears repeatedly in their conclusions.

What makes this work noteworthy is not that it proves cannabis can treat cancer. Rather, it demonstrates that plant tissue culture systems can produce stable, bioactive nanomaterials with measurable immunological effects. The hairy root platform offers reproducibility that field-grown plants cannot match. The nanovesicles survived digestion, which matters for oral delivery. The immune activation was real and followed a coherent mechanistic pathway. These are the building blocks of a credible early-stage research program.

The next steps are well-defined: researchers need to measure oral bioavailability and track where the particles go in the body. They need larger tumor studies with proper controls and dose-response curves. They need to understand whether the effects seen in mice translate to any meaningful degree in larger animals or humans. They need long-term safety data. None of this is guaranteed to work out. But the foundation is solid enough that the question is worth asking.